NEW YORK (GenomeWeb) – German genetic testing firm CeGaT said today that it has received €500,000 ($531,615) from the German Federal Ministry of Education and Research to support the development of liquid biopsy methods for the analysis of circulating tumor DNA.

The funding comes from an initiative called the KMU-Innovativ: Biotechnologie-BioChance.

According to CeGaT, the money will help it expand its genetic analysis services to new patients who would currently be ineligible because they cannot safely undergo a tissue biopsy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.